| SEQ_NO | 1 | Date of announcement | 2024/01/18 | Time of announcement | 17:20:09 |
| Subject | Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix, Inc. | ||||
| Date of events | 2024/01/18 | To which item it meets | paragraph 20 | ||
| Statement | 1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.): The new common shares issued for capital increase by Medeologix, Inc. 2.Date of occurrence of the event:2024/01/18~2024/01/18 3.Volume, unit price, and total monetary amount of the transaction: Transaction Volume: No more than 12,600,000 common shares Issued price per share: NTD 25 Total monetary amount: No more than NTD 315,000,000 4.Trading counterparty and its relationship to the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): Medeologix, Inc., the subsidiary of Medeon Biodesign 5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer: Reason for choosing the related party as the trading counterparty: The subsidiary of Medeon Biodesign Previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer: N/A 6.Where an owner of the underlying assets within the past five years has been an related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship to the Company at the time of the transaction:N/A 7.Matters related to the current disposal of creditors’ rights (including types of collaterals of the disposed creditor’s rights; if creditor’s rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor’s rights, currently being disposed of, over such related party:N/A 8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status of recognition shall be listed and explained):N/A 9.Terms of delivery or payment (including payment period and monetary value), restrictive covenants in the contract, and other important terms and conditions: Terms of delivery or payment: Payment will be made according to the fund raising schedule resolved by Medeologix’s board. 10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit: Medeon Board of Director’s resolution dated 2024/01/18 11.Net worth per share of the Company’s underlying securities acquired or disposed of:NTD 14.03 12.Cumulative no.of shares held (including the current transaction), their monetary value, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment: Cumulative number of shares held (including the current transaction): No more than 52,814,174 shares Cumulative monetary amount: No more than NTD 1,155,000 thousand. Cumulative shareholding percentage: No more than 96.62% The status of any restriction of rights (e.g., pledges): N/A 13.Ratio of securities investment (including the current transaction) to the total assets and shareholder’s equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements, as of the present moment: Current ratio of securities investment to the total assets: 30.93% Current ratio of securities investment to the equity attributable to owners of the parent: 32.11% Working capital: NTD 1,056,411 thousand. 14.Broker and broker’s fee:N/A 15.Concrete purpose or use of the acquisition or disposal: Long-term Equity Investment 16.Whether the directors expressed any objection to the current transaction:N/A 17.Whether the counterparty of the current transaction is a related party:Yes 18.Date of the Board of Directors’ resolution:2024/01/18 19.Date of ratification by supervisors or approval by the Audit Committee:2024/01/18 20.Whether the CPA issued an opinion on the unreasonableness regarding the current transaction:N/A 21.Name of the CPA firm:Horng Yow Certified Public Accountants 22.Name of the CPA:JUYU TANG 23.License no.of the CPA: Financial-Supervisory-Securities-Corporate-0970013154 24.Any other matters that need to be specified:None |
||||